Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The Liver-α-Cell Axis and Type 2 Diabetes

Research output: Contribution to journalReviewResearchpeer-review

DOI

  1. At the crossroads of fate - somatic cell lineage specification in the fetal gonad

    Research output: Contribution to journalReviewResearchpeer-review

  2. Cytokines and beta-cell biology: from concept to clinical translation

    Research output: Contribution to journalReviewResearchpeer-review

  1. Endogenous glucose-dependent insulinotropic polypeptide exerts diverging and tissue specific in obese patients with type 2 diabetes

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  2. Gut-derived glucagon in man

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  3. The glucagon-like peptide-1 receptor agonist, liraglutide, does not suppress postprandial cholecystokinin in patients with type 1 diabetes

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  4. The role of glucagon-like peptide 1 for the postprandial effects of metformin in type 2 diabetes

    Research output: Contribution to journalConference abstract in journalResearchpeer-review

  5. The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion-A Review

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

Both type 2 diabetes (T2D) and nonalcoholic fatty liver disease (NAFLD) strongly associate with increasing body mass index, and together these metabolic diseases affect millions of individuals. In patients with T2D, increased secretion of glucagon (hyperglucagonemia) contributes to diabetic hyperglycemia as proven by the significant lowering of fasting plasma glucose levels following glucagon receptor antagonist administration. Emerging data now indicate that the elevated plasma concentrations of glucagon may also be associated with hepatic steatosis and not necessarily with the presence or absence of T2D. Thus, fatty liver disease, most often secondary to overeating, may result in impaired amino acid turnover, leading to increased plasma concentrations of certain glucagonotropic amino acids (e.g., alanine). This, in turn, causes increased glucagon secretion that may help to restore amino acid turnover and ureagenesis, but it may eventually also lead to increased hepatic glucose production, a hallmark of T2D. Early experimental findings support the hypothesis that hepatic steatosis impairs glucagon's actions on amino acid turnover and ureagenesis. Hepatic steatosis also impairs hepatic insulin sensitivity and clearance that, together with hyperglycemia and hyperaminoacidemia, lead to peripheral hyperinsulinemia; systemic hyperinsulinemia may itself contribute to worsen peripheral insulin resistance. Additionally, obesity is accompanied by an impaired incretin effect, causing meal-related glucose intolerance. Lipid-induced impairment of hepatic sensitivity, not only to insulin but potentially also to glucagon, resulting in both hyperinsulinemia and hyperglucagonemia, may therefore contribute to the development of T2D at least in a subset of individuals with NAFLD.

Original languageEnglish
JournalEndocrine Reviews
Volume40
Issue number5
Pages (from-to)1353-1366
Number of pages14
ISSN0163-769X
DOIs
Publication statusPublished - 1 Oct 2019

ID: 56951217